- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05599802
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
October 30, 2022 updated by: AIM Vaccine Co., Ltd.
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010) in Healthy Participants Aged 18 Years and Older
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
144
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Prof. Dr. M. Raza Shah
- Phone Number: (92-21)37715064
- Email: razashahm@yahoo.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged 18 years and older.
- Understand the content of the ICF, and voluntarily sign the ICF (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed).
- Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
- Female participants of childbearing potential or partners of male participants: voluntarily agree to use effective contraception with their partners prior to the (1st dose of) vaccination and must agree to continue such precautions during the study until 3 months after (full) vaccination.[Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices(IUDs), sterilization, abstinence, condoms (for male), diaphragms, cervical caps, etc.].
- For female participants: without childbearing potential (amenorrhea for at least 1 year or documented surgical sterilization) or have used effective contraception with a negative pregnancy test before (each dose of) vaccination in this study.
- On the day of vaccination and 24 hours prior to (each dose of) vaccination, axillary temperatures<37.3℃/99.1°F.
- Healthy participants or participants with mild underlying disease [in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study].
- (For group 2 and group 3 only) Participants who have received full primary vaccination of licensed SARS-CoV-2 vaccine (3-8 weeks between 2 doses of COVID-19 inactivated vaccine or 2 doses of COVID-19 mRNA vaccine) and whose last dose was given >6 mony
- (For group 1 only) Not have received any COVID-19 vaccine prior to enrollment.
Exclusion Criteria:
- Any screening hematology and/or blood biochemistry laboratory value that meets the definition of a ≥Grade 1 abnormality,
- (For group 1 only) Confirmed SARS-CoV-2 diagnosis within 1 years before screening visit.
- History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), or other coronavirus infections.
- Receipt of medications intended to treat COVID-19 with 1 year.
- History of server adverse reaction associated with a vaccine or drug and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s).
- SARS-CoV-2 RT-PCR positive nasopharyngeal/oropharyngeal swab specimens at screening.
- Positive HIV test at screening.
- A history or family history of convulsions, epilepsy, encephalopathy and psychosis.
- Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period.
- Asplenia of functional asplenia, complete or partial splenectomy from any cause.
- Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids are permitted.
- Any other licensed vaccines given within 28 days prior to the investigational vaccination, or planned administration of vaccine(s) within 28 days after (full) vaccination.
- Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, form 60 days before vaccine administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before vaccine administration, or planned receipt throughout the study.
- Blood donation or blood loss ≥450ml within 1 month prior to enrollment or planned to donate blood during the study period.
- Participation in other studies involving study intervention within 28 days prior to study entry, and/or during the study.
- Women who are pregnant or breastfeeding.
- Participants deemed unsuitable for participation in this study based on the investigator's assessment.
- (For group 1 only: Criteria for delay of 2nd dose of vaccination) Fever within 24 hours prior to the 2nd dose of vaccination (axillary body temperature ≥37.3℃/99.1°F).
- (For group 1 only: Criteria for delay of 2nd dose of vaccination) During treatment/recovery from illness.
- (For group 1 only: Criteria for delay of 2nd dose of vaccination) Other conditions considered by the investigator to be unsuitable for vaccination.
- (For group 1 only: Criteria for termination of 2nd dose of vaccination) Participants with a positive urine pregnancy or blood pregnancy test (women of childbearing age only).
- (For group 1 only: Criteria for termination of 2nd dose of vaccination) Serious allergic reactions or serious adverse events related to vaccination (as assessed by the investigator) following a previous dose of vaccine.
- (For group 1 only: Criteria for termination of 2nd dose of vaccination) Positive result for SARS-CoV-2 (positive RT-PCR test).
- (For group 1 only: Criteria for termination of 2nd dose of vaccination) The investigator considers inappropriate for the participants to continue participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1A: 50μg SARS-CoV-2 variant mRNA vaccine
Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
|
50μg/dose
|
Experimental: 1B: 100μg SARS-CoV-2 variant mRNA vaccine
Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
|
100μg/dose
|
Experimental: 2A: 50μg SARS-CoV-2 variant mRNA vaccine
Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
|
50μg/dose
|
Experimental: 2B: 100μg SARS-CoV-2 variant mRNA vaccine
Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
|
100μg/dose
|
Experimental: 3A: 50μg SARS-CoV-2 variant mRNA vaccine
Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
|
50μg/dose
|
Experimental: 3B: 100μg SARS-CoV-2 variant mRNA vaccine
Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
|
100μg/dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence, severity, and duration of each solicited (local and systemic) AE.
Time Frame: Within 30 minutes and 7 days after (each dose of) vaccination
|
Within 30 minutes and 7 days after (each dose of) vaccination
|
Incidence, severity, and duration of each unsolicited AE.
Time Frame: Within 28 days after (each dose of) vaccination
|
Within 28 days after (each dose of) vaccination
|
The percentage of participants with abnormal hematology and chemistry laboratory values.
Time Frame: 4 days after (each dose of) vaccination
|
4 days after (each dose of) vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric Mean Titer (GMT) of SARS-CoV-2 Virus Neutralizing Antibody (VNA) (live virus assay).
Time Frame: Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Seroconversion Rate (SCR) of SARS-CoV-2 Virus Neutralizing Antibody (VNA) (live virus assay).
Time Frame: Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Geometric Mean Increase (GMI) of SARS-CoV-2 Virus Neutralizing Antibody (VNA) (live virus assay).
Time Frame: Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
GMT of S-protein specific IgG antibodies (ELISA)
Time Frame: Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
SCR of S-protein specific IgG antibodies (ELISA)
Time Frame: Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
GMI of S-protein specific IgG antibodies (ELISA)
Time Frame: Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
Before (each dose of) vaccination, 14 days and 28 days after (each dose of) vaccination
|
The incidence, severity, and causality of Serious Adverse Events (SAEs)
Time Frame: Within 12 months after (full) vaccination
|
Within 12 months after (full) vaccination
|
The incidence, severity, and causality of Adverse Events of Special Interest (AESI)
Time Frame: Within 12 months after (full) vaccination
|
Within 12 months after (full) vaccination
|
The incidence, severity, and causality of the occurrence of pregnancy events
Time Frame: Within 12 months after (full) vaccination
|
Within 12 months after (full) vaccination
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
GMT of SARS-CoV-2 VNA (live virus assay).
Time Frame: 3 months and 6 months after (full) vaccination
|
3 months and 6 months after (full) vaccination
|
SCR of SARS-CoV-2 VNA (live virus assay).
Time Frame: 3 months and 6 months after (full) vaccination
|
3 months and 6 months after (full) vaccination
|
GMI of SARS-CoV-2 VNA (live virus assay).
Time Frame: 3 months and 6 months after (full) vaccination
|
3 months and 6 months after (full) vaccination
|
GMT of S-protein specific IgG antibodies (ELISA)
Time Frame: 3 months and 6 months after (full) vaccination
|
3 months and 6 months after (full) vaccination
|
SCR of S-protein specific IgG antibodies (ELISA)
Time Frame: 3 months and 6 months after (full) vaccination
|
3 months and 6 months after (full) vaccination
|
GMI of S-protein specific IgG antibodies (ELISA)
Time Frame: 3 months and 6 months after (full) vaccination
|
3 months and 6 months after (full) vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Prof. Dr. M. Raza Shah, Center for Bioequivalence Studies and clinical research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2023
Primary Completion (Anticipated)
May 1, 2023
Study Completion (Anticipated)
May 1, 2024
Study Registration Dates
First Submitted
October 26, 2022
First Submitted That Met QC Criteria
October 26, 2022
First Posted (Actual)
October 31, 2022
Study Record Updates
Last Update Posted (Actual)
November 1, 2022
Last Update Submitted That Met QC Criteria
October 30, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LVRNA010-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
Clinical Trials on SARS-CoV-2 variant mRNA vaccine low dose
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Recruiting
-
Sanofi Pasteur, a Sanofi CompanyTerminatedCOVID-19United States, Australia, Brazil, Honduras
-
University of MelbourneSouthern Star Research Pty Ltd.Completed
-
Ihsan GURSEL, PhD, Prof.The Scientific and Technological Research Council of Turkey; MonitorCRO; Nobel...Completed
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | COVID-19 InfectionUnited States
-
NYU Langone HealthCompletedMultiple SclerosisUnited States
-
TruDiagnosticCornell UniversityActive, not recruiting